Literature DB >> 9493135

Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature.

J F Vansteenkiste1, P R De Leyn, G J Deneffe, T E Lerut, M G Demedts.   

Abstract

There remains controversy on the prognostic value of several common clinical factors in NSCLC patients with resected N2-disease. The aim of this paper is to give a comprehensive overview of the available data on this issue. Literature data on surgically treated N2-NSCLC-patients from 1980-1995, peer reviewed and listed in Index Medicus, were analysed. Reported and calculated or estimated survival data were indexed. Eighteen series were selected: in 12 of them, direct comparisons between survival curves of subgroups are reported; six contained sufficient data to make comparisons of survivors at 5 years; three of them also made a multivariate Cox model. The analysis of prognostic factors in a single study was often hampered by the limited number of patients. Nonetheless, it could be concluded that patients with a clinical N0- or N1-status (so-called unforeseen N2) do better. There was no clear difference between patients undergoing lobectomy or pneumonectomy. There was strong evidence that N2-patients with a less advanced primary tumour (T-stage) have a better prognosis, and this is the case for all operable T-stages (T1 versus T2, T1 versus T3, T2 versus T3). Squamous cell type was a favourable prognostic factor, as was the presence of only one metastatic mediastinal lymph node station or absence of metastases to the subcarinal nodes. There was some evidence that the presence of extracapsular spread in metastatic MLN is an unfavourable finding. Stratification for these prognostic factors could help in the planning of future trials on combined modality treatment in N2-NSCLC.

Entities:  

Mesh:

Year:  1998        PMID: 9493135     DOI: 10.1016/s0169-5002(97)00072-x

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  15 in total

1.  The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer.

Authors:  Qinchen Cao; Baozhong Zhang; Lujun Zhao; Changli Wang; Liqun Gong; Jun Wang; Qingsong Pang; Kai Li; Weishuai Liu; Xue Li; Peng Wang; Ping Wang
Journal:  Tumour Biol       Date:  2015-01-27

2.  Survival impact of node zone classification in resected pathological N2 non-small cell lung cancer.

Authors:  Tetsuro Baba; Hidetaka Uramoto; Taiji Kuwata; Yasuhiro Chikaishi; Makoto Nakagawa; Tomoko So; Takeshi Hanagiri; Fumihiro Tanaka
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-27

3.  Cost-effectiveness associated with the diagnosis and staging of non-small-cell lung cancer.

Authors:  H Osada; K Kojima; H Tsukada; Y Nakajima; K Imamura; J Matsumoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-01

4.  Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution.

Authors:  Honghai Dai; Zhouguang Hui; Wei Ji; Jun Liang; Jima Lu; Guangfei Ou; Zongmei Zhou; Qinfu Feng; Zefen Xiao; Dongfu Chen; Hongxing Zhang; Weibo Yin; Jie He; Luhua Wang
Journal:  Oncologist       Date:  2011-04-11

5.  The Significance of Upfront Knowledge of N2 Disease in Non-small Cell Lung Cancer.

Authors:  Daniel C Thomas; Brian N Arnold; Joshua E Rosen; Michelle C Salazar; Frank C Detterbeck; Justin D Blasberg; Daniel J Boffa; Anthony W Kim
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

6.  Radical systematic mediastinal lymphadenectomy versus mediastinal lymph node sampling in patients with clinical stage IA and pathological stage T1 non-small cell lung cancer.

Authors:  Kai Ma; Dong Chang; Baoliang He; Min Gong; Feng Tian; Xiaodan Hu; Zhongyi Ji; Tianyou Wang
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-27       Impact factor: 4.553

Review 7.  The role of surgery in the treatment of stage III non-small-cell lung cancer.

Authors:  Amy E Gallo; Jessica S Donington
Journal:  Curr Oncol Rep       Date:  2007-07       Impact factor: 5.075

Review 8.  Management of locally advanced non small cell lung cancer from a surgical perspective.

Authors:  Millie S Roy; Jessica S Donington
Journal:  Curr Treat Options Oncol       Date:  2007-02

9.  Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy.

Authors:  Zhouguang Hui; Honghai Dai; Jun Liang; Jima Lv; Zongmei Zhou; Qinfu Feng; Zefen Xiao; Dongfu Chen; Hongxing Zhang; Weibo Yin; Luhua Wang
Journal:  Thorac Cancer       Date:  2015-04-24       Impact factor: 3.500

10.  The prognostic significance of multiple station N2 in patients with surgically resected stage IIIA N2 non-small cell lung cancer.

Authors:  Jin Gu Lee; Chang Young Lee; In Kyu Park; Dae Joon Kim; Sang Ho Cho; Kil Dong Kim; Kyung Young Chung
Journal:  J Korean Med Sci       Date:  2008-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.